Back to results
US 7,731,945 B2Granted
Immunotherapy for reversing immune suppression
AssigneeImmuno-Rx, Inc.
InventorJohn W. Hadden
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeImmuno-Rx, Inc.
InventorJohn W. Hadden
Estimating the term…
A method for overcoming immune suppression includes the steps of inducing production of naïve T cells and restoring T cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T cells and exposing the naïve T cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T cells to gain immunization of the T cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions; preferably the natural cytokine mixture is administered in combination with thymosin α1.
A method for unblocking immunization at a lymph node regional to a lesion to be treated in a cancer patient by administering a natural cytokine mixture (NCM) in combination with thymosin α1 into lymphatics that drain into said lymph node, inducing production of CD45RA positive naïve T cells, promoting maturation and activation of dendritic cells in said regional lymph node and allowing presentation by resulting mature dendritic cells of tumor antigen to CD45RA positive naïve T cells to gain immunization of the CD45RA positive naïve T cells to the tumor antigen, and measuring naïve T cells by detecting CD45RA positive T cells, wherein the detection of an increase in CD45RA positive naïve T cells correlates with an improved immune response to tumor antigen.
A method for overcoming T cell depletion in an immune depressed cancer patient by administering to the patient a NCM in combination with thymosin α1, inducing production of CD45RA positive naïve T cells and restoring T cell immune responses in the patient, and measuring naïve T cells by detecting CD45RA positive T cells, wherein the detection of an increase in CD45RA positive naïve T cells correlates with an improved immune response to tumor antigen.
A method for unblocking immunization at a lymph node regional to a lesion to be treated in a cancer patient by inducing production of CD45RA positive naïve T cells, promoting maturation and activation of dendritic cells in said regional lymph node and allowing presentation by resulting mature dendritic cells of tumor antigen to the CD45RA positive naïve T cells to gain immunization of the CD45RA positive naïve T cells to the antigen, and measuring naïve T cells by detecting CD45RA positive T cells, wherein the detection of an increase in CD45RA positive naïve T cells correlates with an improved immune response to tumor antigen, and wherein said promoting step is further defined as administering a natural cytokine mixture (NCM) in combination with thymosin α1 into lymphatics that drain into said lymph node, the NCM being produced in the presence of a 4-aminoquinolone antibiotic.
A method for overcoming T cell depletion in an immune depressed cancer patient by inducing production of CD45RA positive naïve T cells and restoring T cell immune responses in the patient comprising an administering step defined as administering to the patient a NCM in combination with thymosin α1, the NCM being produced in the presence of a 4-aminoquinolone antibiotic, and measuring naïve T cells by detecting CD45RA positive T cells, wherein the detection of an increase in CD45RA positive naïve T cells correlates with an improved immune response to tumor antigen.
A method of treating a cancer in an immune suppressed patient by administering to the patient an effective amount of a NCM comprising IL-1, IL-2, IL-6, IL-8, TNFα, and IFN-γ in combination with thymosin α1, the NCM being produced in the presence of a 4-aminoquinolone antibiotic, which combination acts as an adjuvant stimulating an immune response in the patient, wherein said stimulating step is further defined as inducing production of CD45RA positive naïve T cells, promoting maturation and activation of dendritic cells in a regional lymph node and allowing presentation by resulting mature dendritic cells of tumor antigen to CD45RA positive naïve T cells to gain immunization of the CD45RA positive naïve T cells to the antigen, and measuring naïve T cells by detecting CD45RA positive T cells, wherein the detection of an increase in CD45RA positive naïve T cells correlates with an improved immune response to tumor antigen.
Dependencies are inferred from the claim text.